SCHEMBL3699549

SCHEMBL3699549

COc1cc2c(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)cc3F)ccnc2cc1OCC1(N)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.55
KDR P35968 8/20 0.55
AXL P30530 6/20 0.55
PDGFRB P09619 4/20 0.52
RET P07949 4/20 0.51
KIT P10721 3/20 0.51
FLT3 P36888 3/20 0.51
HDAC2 Q92769 2/20 0.51
HDAC8 Q9BY41 2/20 0.51
HDAC6 Q9UBN7 2/20 0.51
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
MERTK Q12866 3/20 0.49
FGFR1 P11362 4/20 0.48
FLT1 P17948 4/20 0.48
FLT4 P35916 4/20 0.48
RIPK2 O43353 3/20 0.48
LYN P07948 3/20 0.48
DDR1 Q08345 3/20 0.48
DDR2 Q16832 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31412944 0.93 MET (0.62) METKDRAXLPDGFRBRET
SCHEMBL408158 0.93 MET (0.62) METKDRAXLPDGFRBRET
SCHEMBL3675221 0.93 MET (0.55) METKDRAXLPDGFRBRET
SCHEMBL28676846 0.91 MET (0.57) METKDRAXLPDGFRBRET
Hydrochloric Acid SCHEMBL15918148 0.90 MET (0.56) METKDRAXLPDGFRBRET
Hydrochloric Acid SCHEMBL15917934 0.90 MET (0.56) METKDRAXLPDGFRBRET
Hydrochloric Acid SCHEMBL15917992 0.90 MET (0.56) METKDRAXLPDGFRBRET
SCHEMBL28678364 0.89 MET (0.55) METKDRAXLPDGFRBRET
SCHEMBL28686931 0.89 HDAC2 (0.57) METKDRAXLPDGFRBRET
SCHEMBL31412923 0.89 MET (0.57) METKDRAXLPDGFRBRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621904-B1 COMPOUNDS AS C-MET KINASE INHIBITORS ADVENCHEN LABORATORIES LLC (US) 2020-04-22 EP claimed
US-8664244-B2 Compounds as c-Met kinase inhibitors Advenchen Pharmaceuticals, LLC (US) 2014-03-04 US claimed
US-20120123126-A1 Compounds As c-Met Kinase Inhibitors CHEN GUOQING PAUL (US) 2012-05-17 US claimed
EP-2621904-B1 COMPOUNDS AS C-MET KINASE INHIBITORS ADVENCHEN LABORATORIES LLC (US) 2020-04-22 EP disclosed
US-8664244-B2 Compounds as c-Met kinase inhibitors Advenchen Pharmaceuticals, LLC (US) 2014-03-04 US disclosed
US-20120123126-A1 Compounds As c-Met Kinase Inhibitors CHEN GUOQING PAUL (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120123126-A1 Compounds As c-Met Kinase Inhibitors MET, MERTK, HGF MET 1/4885KDR 22/4885AXL 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.